MedTrace Logo

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

NCT00730717 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-02-15

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.

Conditions

  • Pyoderma Gangrenosum

Interventions

DRUG

Humira

Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23

DRUG

Humira

Will receive 40 mg Humira injection every other week from Week 0 to Week 23

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • Wake Forest University Health Sciences

    collaborator OTHER

  • Wright State University

    lead OTHER

Principal Investigators

  • David F Fiorentino, MD, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730717 on ClinicalTrials.gov